[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Richmond Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":134},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,64,85,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100446840","pathway-rct-preventing-admission-to-hospital-with-attr-cardiomyopathy-100446840",false,"NCT05098665","PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY","PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY Using Remote Cardiac Telemonitoring","PATHWAY-RCT","Inclusion Criteria:\n\n1. Adults aged ≥18 at the date of signing informed consent which is defined as the beginning of the Screening Period.\n2. An established diagnosis of ATTR cardiomyopathy as defined by protocol.\n3. Ability to provide written, personally signed and dated informed consent to participate in the study, in accordance with the ICH Good Clinical Practice (GCP) Guideline E6 (R2) (2016) and applicable regulations, before completing any study-related procedures.\n4. An understanding, ability, and willingness to fully comply with study procedures and restrictions.\n5. Currently a patient at a study site (NAC).\n\nExclusion Criteria:\n\n1. An inability to have or use BodyTrace device scales at usual residence (for example no mobile network cellular signal)\n2. On dialysis or end-stage renal failure (eGFR \\\u003C25mL\u002Fmin)\n3. Serum albumin \\\u003C20g\u002FdL or other non-hypervolaemia cause of tissue oedema (e.g. protein-losing enteropathy, nephrotic syndrome)\n4. Use of greater than 2 oral diuretics (e.g. on maximum oral diuretic therapy)","ALL","18 Years",{"count":20,"type":21},320,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cardiac amyloidosis is a condition where the heart muscle, amongst other tissues, is infiltrated by the abnormal build-up of proteins called amyloid. This stiffens and thickens the heart muscle over time which makes it less efficient and puts further stress and strain on the other chambers of the heart, leading to heart failure. The commonest form, that affects predominantly the elderly, is called 'wild-type' ATTR amyloid (TTR is the protein that accumulates). In this condition a patient has a 60% chance of admission to hospital each year after diagnosis. There is no current treatment for ATTR amyloid other than using water tablets to reduce excess fluid and prevent more serious fluid build up in lungs and other tissues. Increasing body weight is the most reliable clinical sign of this fluid build up.\n\nTele-monitoring is the practice of monitoring patients from a distance and has been shown to reduce heart failure admissions and death in patients with heart failure from any cause. Due to reduced access to primary and secondary care during COVID-19 the investigators instigated tele-monitoring of heart failure in ATTR amyloid patients. This appeared to be an effective intervention in the pilot study. The investigators propose to monitor the weight of patients with cardiac amyloidosis at home and intervene where a build up of fluid is observed by telephone discussion with a doctor. The investigators propose to evidence this in a prospective clinical trial. The investigators will evaluate the effect fairly by comparing tele-monitoring with usual care.",[27],"Cardiac Amyloidosis","RECRUITING","2026-06-15",{"date":31,"type":32},"2026-06-16","ACTUAL",{"date":34,"type":32},"2025-01-01",{"date":36,"type":21},"2027-12",{"name":38,"class":39},"Richmond Research Institute","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100393517","serological-and-pcr-testing-for-covid-19-100393517","NCT04404062","Serological and PCR Testing for COVID-19","Serological and PCR Testing for SARS-CoV-2. A Prospective Study Assessing Infection, Immunity, and Asymptomatic Carriage of COVID-19","Inclusion Criteria:\n\n* Male or female aged 5 to 70 years.\n* An understanding, ability, and willingness to fully comply with the project procedures and restrictions.\n\nExclusion Criteria:\n\n* Not applicable.",true,"5 Years","70 Years",{"count":52,"type":21},2500,"OBSERVATIONAL","Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results. Infection with coronavirus (SARS-CoV-2) is currently a worldwide pandemic and reliable testing for COVID-19 is crucial to understand who is infected and therefore a risk to others by spreading the infection. RRI are currently carrying out the following tests:\n\nA. Using a membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens helps to assess whether an individual has previously had the virus and is potentially immune\n\nB. Polymerase Chain Reaction (PCR) testing using an established method to check for active SARS-CoV-2 infections.\n\nC. Quantification of anti-SARS-CoV-2 IgG and IgM antibodies in whole blood samples.\n\nThe above tests are being used by RRI to follow infections (PCR) and immunity (IgG) in their workforce, as well as their families (including children) and visitors to their site.\n\nCollecting this data allows the gathering of epidemiological data on SARS-CoV-2 including incidence, prevalence, information on asymptomatic carriers and efficacy of vaccination. Furthermore, identifying individuals that are infected with SARS-CoV-2 has great potential to improve health outcomes by allowing infected individuals to seek the correct medical treatment as well as self-isolate and reduce transmission.",[56],"COVID-19",{"date":58,"type":32},"2026-06-17",{"date":60,"type":32},"2020-03-16",{"date":62,"type":21},"2028-12",{"name":38,"class":39},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100639633","engagement-study-for-participants-with-factor-v-leiden-and-prothrombin-g20210a-mutations-100639633","NCT07584265","Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations","Engagement Study to Establish a Clinical Baseline for Adult Participants With Factor V Leiden or Prothrombin G20210A Mutation and Familiarise Them With the Clinical Trials Unit Environment for Future Clinical Trial Participation.","Inclusion Criteria:\n\n1. Male or female participants aged ≥ 18 years at the date of signing the Participant Information Sheet\u002FInformed Consent Form (PIS\u002FICF).\n2. Ability to provide written, personally signed, and dated informed consent in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines E6 (R3) (2025) and applicable regulations, before any study-specific procedures are performed.\n3. Confirmed or suspected diagnosis of FVL or Prothrombin G20210A mutation via targeted genetic testing.\n\nExclusion Criteria:\n\n1. Unwilling or unable to comply with the protocol-defined study assessments.\n2. Any other significant disease or disorder that, in the opinion of the Principal Investigator (PI) or Sponsor, may either place the participant at risk from participation, or influence the clinical baseline.",{"count":72,"type":21},100,"This study will enrol individuals who have, or may have, Factor V Leiden or Prothrombin G20210A mutations, which are genetic changes linked to an increased risk of blood clots. Targeted genetic testing will be carried out, where appropriate, to confirm whether participants have one of these genetic variants. Those with a confirmed result will attend a site visit for basic health checks, including blood pressure measurements, ECG, and blood tests, to establish a baseline of their general health and help identify suitability for future related clinical trials.\n\nThe study also provides participants with the opportunity to learn more about clinical research and become familiar with the clinical trial unit and team. Participation lasts approximately 10 weeks and includes 1-2 site visits and a follow-up telephone call.",[75,76],"Factor V Leiden","Prothrombin G20210A","2026-05-26",{"date":79,"type":32},"2026-05-29",{"date":81,"type":32},"2026-04-21",{"date":83,"type":21},"2027-01-31",{"name":38,"class":39},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100578314","study-to-collect-high-resolution-ecg-data-and-patient-insights-on-heart-failure-care-100578314","NCT06809686","Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care","An Observational Study to Collect High Resolution 12-Lead Electrocardiogram (ECG) Data for the Development of an ECG Library to Support the Development of a Tool to Monitor Disease Progression, Gather Patient Perspectives on Standard of Care Heart Failure Procedures and Facilitate Familiarity With the Clinical Trial Environment in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction","Inclusion Criteria:\n\n1. Male or female participants aged 45 to 80 years (inclusive) at the date of signing the informed consent.\n2. Diagnosed with heart failure.\n3. Able and willing to provide informed consent to participate.\n\nExclusion Criteria:\n\n1. Diagnostic test results positive for:\n\n   1. HIV-1 or HIV-2 infection\n   2. Hepatitis B or Hepatitis C infection\n2. Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or cooperation during the study as judged by the Investigator.\n3. Any condition judged by the Investigator to pose an undue risk while participating in the trial\n4. Diagnostic results which are inconsistent with heart failure with mildly reduced or preserved ejection fraction as judged by the Investigator.","45 Years","80 Years",{"count":95,"type":21},1000,"The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease. Additionally, the study will be used to monitor changes in the patient's standard of care throughout the study period and gather patient perspectives on routine diagnostic procedures and disease monitoring and feedback on the design of heart failure trials.",[98],"Heart Failure","2026-05-18",{"date":101,"type":32},"2026-05-20",{"date":103,"type":32},"2025-02-05",{"date":105,"type":21},"2027-02-21",{"name":38,"class":39},2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":116,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":40},"100429529","development-of-a-non-invasive-screening-tool-to-predict-metabolic-dysfunction-associated-steatotic-liver-disease-100429529","NCT04873258","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Volunteers on Clinical Trials Utilising Machine-learning and Bioimpedance Vector Analysis","MASLD","Inclusion Criteria:\n\n1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent.\n2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations.\n3. An understanding, ability and willingness to fully comply with project procedures and restrictions.\n\nFor PART B only:\n\n1\\. With a known history of MASLD as evidenced either of:\n\n1. GP diagnosis on HCF\n2. Documented Fibroscan or liver US demonstrating MASLD\n\nExclusion Criteria:\n\n1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other)\n2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease)\n3. Alcohol consumption \\>30 units per week\n4. An Implanted cardiac devices",{"count":117,"type":21},2000,"A generic screening study to establish structural and\u002For functional baselines of specific organs.",[120,121,114,122,123],"Healthy","Fatty Liver","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Obesity and Obesity-related Medical Conditions",[125,114],"Fatty liver","2025-07-18",{"date":128,"type":32},"2025-07-23",{"date":130,"type":32},"2019-09-27",{"date":132,"type":21},"2027-12-31",{"name":38,"class":39},""]